Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Influenza B virus hemagglutinin. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
Clonality | Monoclonal |
Host Species | Human |
Target Species | Influenza B virus (IBV) |
Immunogen | IBV Hemagglutinin |
Isotype | IgG, κ |
Expression Species | HEK293F or CHO |
Conjugation | None |
Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
Endotoxin | <1 EU/mg, determined by LAL method |
Purification | Protein A affinity purified |
Sterility | 0.2 μM filtered |
Formulation | PBS, pH 7.4 |
Preservation | No preservatives |
Stabilizer | No stabilizers |
Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
Application | DB; WB; ELISA; Neut |
Application Notes | The antibody is recommended for detection of IBV HA by WB (1/1000-1/5000), ELISA (1/1000-1/20000), Neut assays. |
ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
WB | Western Blot Protocol |
FC | Flow Cytometry Protocol |
Figure 1 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in SDS-PAGE
SDS-PAGE analysis of V3S-0522-YC8122 in non-reduced and reduced conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively.
Figure 1 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in SDS-PAGE
Figure 2 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in ELISA
ELISA analysis of V3S-0522-YC8122 was performed by coating with Influenza B (B/Florida/4/2006) Hemagglutinin / HA Protein (His Tag).
Antigen: 2 μg/ml, 100 μL/well
The secondary antibody: HRP-Anti-Human IgG (H+L)
Figure 2 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in ELISA
Figure 3 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in WB
Western blot analysis of V3S-0522-YC8122 was performed by loading Influenza B (B/Florida/4/2006) Hemagglutinin / HA Protein (His Tag).
V3S-0522-YC8122 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane1: Reducing antigen (0.1 μg)
Lane2: Reducing antigen (0.3 μg)
Lane3: Reducing antigen (0.6 μg)
Figure 3 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in WB
Figure 4 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in DB
Dot Blot analysis of V3S-0522-YC8122 was performed by coating with Influenza B (B/Florida/4/2006) Hemagglutinin / HA Protein (His Tag).
V3S-0522-YC8122 incubation concentration: 2 ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Figure 4 Recombinant Human Anti-IBV HA Monoclonal Antibody (V3S-0522-YC8122) in DB